NCT01146782已完成不适用
The ATLAST Trial - A Multicenter, Prospective Study of the Attune Sleep Apnea System for the Treatment of Obstructive Sleep Apnea (OSA)
适应症
试验速览
- 阶段
- 不适用
- 状态
- 已完成
- 入组人数
- 367
- 试验地点
- 12
- 主要终点
- Clinical Success Defined as Apnea-hypopnea Index (AHI) Reduction of >50% and Treated AHI<20
研究概览
简要总结
This is a prospective study of the Attune Sleep Apnea System for the treatment of obstructive sleep apnea. The objective of the study is to demonstrate safety and effectiveness of the Attune Sleep Apnea System to support FDA marketing clearance of the device.
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- Single (Outcomes Assessor)
入排标准
- 年龄范围
- 18 Years 至 80 Years（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Subject is between the ages of 18 and
- •Diagnosis of OSA, based on ODI 10-60 (as assessed per home screening night).
- •Subject is fluent in English and understands the Study protocol and is willing and able to comply with Study requirements and sign the informed consent form.
- •Subject has a least one molar in each of the four quadrants of the mouth (right upper, right lower, left upper, and left lower).
- •Subject has proper mouthpiece fit, as assessed by home screening night (See section 8.3).
排除标准
- •OSA treatment within two weeks prior to Medical/Dental screening visit.
- •Poor nasal patency as evidenced by Peak Nasal Inspiratory Flow (PNIF) less than 75 l/min (assessed at baseline medical visit). In addition, any ongoing process or condition that limits nasal breathing or indications thereof, including: obligate mouth-breathing, persistent blockage of one or both nostrils resulting in the inability to sleep with the mouth closed, chronic nasal congestion, chronic allergic rhinitis, and intermittent allergic rhinitis that does not respond to non-sedating/non-stimulating medical therapy.
- •Oral cavity infection or any other oral or dental condition or problem that would limit subject use of the Attune Sleep Apnea System (e.g. dentures, loose tooth/teeth, temporomandibular joint (TMJ) conditions, or any oral or dental condition that the Investigator believes could be exacerbated by the Attune Sleep Apnea System.
- •Prior use of the Attune Sleep Apnea System.
- •History of any OSA surgical treatment including uvulopalatopharyngoplasty surgery (UPPP), maxillomandibular advancement surgery (MMA), radio frequency (RF) ablation treatment, palatal stent devices, etc.
- •Current use or use within the previous 2 weeks of medications or other agents that may affect sleep or PSG, including:
- •Hypnotics, anxiolytics, anticonvulsants, sedating antihistamines, stimulants, sedating antidepressants or other medications likely to affect neurocognitive function and/or alertness. Patients on stable selective serotonin reuptake inhibitor (SSRI) therapy for > 3 months and who are expected to remain on therapy for the Study duration, may continue SSRI treatment.
- •Consumption of > 500mg caffeine per day (e.g. > 8 cola-type beverages, > 5 cups of coffee).
- •Any known illicit drug use or abuse within the past year, or failure to pass drug urine screen test, or alcohol breathalyzer test with result over 0.05% BAL.
- •Smokers who smoke during the night (interference with PSG).
- •Any concomitant diagnosed or suspected sleep or chronic neurological disorders, other than OSA, including insomnia, and central sleep apnea.
- •Currently working nights, rotating night shifts, planned travel across four or more time zones required during Study period, or within two weeks prior to Study enrollment, or sleep schedule not compatible with sleep lab practices.
- •Potential sleep apnea complications that, in the opinion of the investigator, may affect the health or safety of the participant, including: low blood oxygen, recent near-miss or prior automobile accident due to sleepiness, reported history of severe cardiovascular disease (including NYHA class III or IV heart failure, CAD with angina or MI/stroke in past 6 months, uncontrolled hypertension or hypotension, cardiac arrhythmias), reported respiratory disorders, or use of medication or other treatment which may pose additional risk to the subject or confound the results of the Study.
- •Female subjects who are pregnant or intend to become pregnant during the study period.
结局指标
主要结局
Clinical Success Defined as Apnea-hypopnea Index (AHI) Reduction of >50% and Treated AHI<20
时间窗: first treatment night
Comparing first treatment night AHI to control/baseline night. AHI is calculated by dividing the number of apnea/hypopnea events by the number of hours of sleep. AHI values are typically characterized as 5-15/hr = mild OSA, 15-30/hr = moderate OSA, and \>30/hr = severe OSA. For each subject, Clinical success was defined as apnea-hypopnea index (AHI) reduction of \>50% and treated AHI\<20. The number of subjects with clinical success was determined to calculate the primary endpoint as the ratio of the number of subjects with clinical success to the number of subjects.
次要结局
- Last Treatment Night Response (AHI Reduction)(At completion of 28 day home use.)
- Percent Reduction in Oxygen Desaturation Index (ODI)(First treatment night)
- Adverse Event Rate(4 weeks)
研究者
研究点 (12)
Loading locations...
相似试验
已完成
不适用
Face of SleepinessObstructive Sleep ApneaNCT01060436University of Michigan30
已完成
不适用
Interest of Treatment of Obstructive Sleep Apnea Syndrome by Constant CPAP and Auto CPAPObstructive Sleep Apnea SyndromesNCT02749812Poitiers University Hospital800
已完成
2 期
Obstructive Sleep Apnea (OSA) Treated With a Potassium Channel InhibitorSleep Apnea, ObstructiveNCT03603678Bayer34
已完成
不适用
Dental Device for Treatment of Sleep ApneaSleep Apnea SyndromesNCT01005940Ulysses Magalang MD20
Unknown
不适用
Management of Sleep Apnoea Syndrome (SAS) in Patients With Vasovagal Syncope (VVS)Syncope, VasovagalSleep Apnea SyndromesNCT04294524PEAS (Pole d'Exploration des Apnees du Sommeil)60